

## **Ankylosing Spondylitis Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)**

Market Report | 2023-01-23 | 120 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The Global Ankylosing Spondylitis Market is expected to grow at a CAGR of 6.4% during the forecast period (2023 - 2028).

The COVID-19 pandemic impacted the ankylosing spondylitis market due to disruptions in various clinical studies and supply chains. Ankylosing spondylitis drug suppliers faced several challenges due to travel restrictions, business closures, stay-at-home protocols, and trade bans during the pandemic. Additionally, precautionary measures taken by governments like social distancing and restrictions have severely disrupted the patient's treatments in the hospital. The pandemic and emergence of variants continue to cause, concern, and sudden and drastic downturn in the economic activity of several countries. This has expected to decline in the market growth during the pandemic.

The growth of the global ankylosing spondylitis drug market is majorly driven by an increase in the prevalence rate of the target disease. According to the article published by the Scandinavian Journal of Rheumatology in 2022, titled "Psoriatic arthritis, axial spondylitis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents", the prevalence rate of spondylitis was 0.41%. Furthermore, the recent advancement in therapy, growing awareness about diagnostics and treatments for the disease, development of effective drugs are the major contributors to the growth of the market. Additionally, government initiatives and advanced healthcare infrastructure are expected to propel market growth over the forecast period.

Many companies are investing on large scale in research and development of ankylosing spondylitis drugs and therapies. Moreover, they are collaborating and adopting merger and acquisitions strategies for getting a stronger investment for the drugs. Thus, the rise in R&D investment is positively influencing the market growth. For instance, Bowie Shenqi Pill (Shanghai University of Traditional Chinese Medicine), Bimekizumab (UCB Biopharma), and Namilumab (Takeda Pharmaceuticals International GmbH) drugs are under development phase. This is expected to propel the market growth over the forecast period.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Due to a lack of awareness regarding ankylosing spondylitis in many nations, many individuals do not seek medical care and instead treat it as a normal ache. This scenario is particularly common in developing countries, which results in restraining the growth of the market.

#### Ankylosing Spondylitis Treatment Market Trends

##### Medication Segment is Expected to Hold a Large Share in the Market

Medication dominated the market in 2021 and is expected to grow during the forecast period due to the rise in ankylosing spondylitis patients and an increase in the adoption of medications for the treatment. Medication is focused on reducing the discomfort caused due to ankylosing spondylitis. Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, disease-modifying antirheumatic drugs such as methotrexate, and biologics including anti-TNF, and anti-IL7 drugs are some of the medications used to reduce pain and swelling.

Furthermore, new product launches are likely to fuel the treatment market, as they are used as the first line of treatment. For instance, in December 2021, Pfizer received approval from the United States Food and Drug Administration (FDA) for tofacitinib, known as Xeljanz or Xeljanz XR, a new medication to treat ankylosing spondylitis (AS) and other disorders like rheumatoid arthritis, juvenile Idiopathic Arthritis. Additionally, in October 2020, Cadila Pharmaceuticals launched the biosimilar of adalimumab, Cadalimab in India which is used to treat psoriatic arthritis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

##### North America Dominates the Market and is Expected to do the Same Over the Forecast Period

North America is anticipated to dominate the ankylosing spondylitis treatment market due to the rise in incidences and prevalence of target diseases, the presence of key players, well-established infrastructure in the region, and the increasing adoption of the latest technologies for better diagnosis options. As per the statistics published by The National Center for Biotechnology Information, in 2021, the prevalence of ankylosing spondylitis is approximately 5% to 6% in people who are HLA-B27 positive.

In addition, the approvals of drugs in the region for the treatment of ankylosing spondylitis are further boosting the growth of the market. For instance, In Feb 2020, Taltz (ixekizumab) received approval from Health Canada for treating adults with ankylosing spondylitis who failed to respond to other treatments. Furthermore, rapid adoption of new therapies and treatment options, raising awareness, and high healthcare expenditure in the region are expected to boost the market share of the region in the industry.

##### Ankylosing Spondylitis Treatment Market Competitor Analysis

The global ankylosing spondylitis treatment market is moderately competitive with several players across the globe. The majority of the key player is involved in the research and manufacturing of ankylosing spondylitis therapy drugs. These market players have gained a high market share and offer a wide range of products with an extensive distribution system across the world. Some of the major key players are Novartis, Amgen, Boehringer Ingelheim International GmbH, UCB Biopharma, and AbbVie.

##### Additional Benefits:

The market estimate (ME) sheet in Excel format  
3 months of analyst support

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## **Table of Contents:**

### 1 INTRODUCTION

#### 1.1 Study Assumptions and Market Definition

#### 1.2 Scope of the Study

### 2 RESEARCH METHODOLOGY

### 3 EXECUTIVE SUMMARY

### 4 MARKET DYNAMICS

#### 4.1 Market Overview

#### 4.2 Market Drivers

##### 4.2.1 Growing Burden of Target Diseases

##### 4.2.2 Development and Commercialization of effective Product

#### 4.3 Market Restraints

##### 4.3.1 Huge cost of treatment

#### 4.4 Porter's Five Force Analysis

##### 4.4.1 Threat of New Entrants

##### 4.4.2 Bargaining Power of Buyers/Consumers

##### 4.4.3 Bargaining Power of Suppliers

##### 4.4.4 Threat of Substitute Products

##### 4.4.5 Intensity of Competitive Rivalry

### 5 MARKET SEGMENTATION (Market Size by Value-USD million)

#### 5.1 By Treatment Types

##### 5.1.1 Medication

###### 5.1.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

###### 5.1.1.2 TNF Inhibitors

###### 5.1.1.3 IL-17 Inhibitors

###### 5.1.1.4 Others

##### 5.1.2 Therapy

##### 5.1.3 Surgery

#### 5.2 Geography

##### 5.2.1 North America

###### 5.2.1.1 United States

###### 5.2.1.2 Canada

###### 5.2.1.3 Mexico

##### 5.2.2 Europe

###### 5.2.2.1 Germany

###### 5.2.2.2 United Kingdom

###### 5.2.2.3 France

###### 5.2.2.4 Italy

###### 5.2.2.5 Spain

###### 5.2.2.6 Rest of Europe

##### 5.2.3 Asia-Pacific

###### 5.2.3.1 China

###### 5.2.3.2 Japan

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.3.3 India
- 5.2.3.4 Australia
- 5.2.3.5 South Korea
- 5.2.3.6 Rest of Asia-Pacific
- 5.2.4 Middle East
  - 5.2.4.1 GCC
  - 5.2.4.2 South Africa
  - 5.2.4.3 Rest of Middle East
- 5.2.5 South America
  - 5.2.5.1 Brazil
  - 5.2.5.2 Argentina
  - 5.2.5.3 Rest of South America

## 6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
  - 6.1.1 Novartis AG
  - 6.1.2 AbbVie Inc.
  - 6.1.3 UCB
  - 6.1.4 Amgen Inc.
  - 6.1.5 Boehringer Ingelheim International GmbH
  - 6.1.6 Celltrion Healthcare
  - 6.1.7 Reliance Life Sciences
  - 6.1.8 Janssen CarePath
  - 6.1.9 Sandoz International GmbH
  - 6.1.10 Pfizer

## 7 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Ankylosing Spondylitis Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)**

Market Report | 2023-01-23 | 120 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-01"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

